Schizophrenia and Psychoses Archive
The quality of diabetes care was examined in patients with and without schizophrenia in a Danish nationwide cohort.
In patients with schizophrenia, long-acting injectable formulations of paliperidone palmitate delay relapse significantly after withdrawal.
Dopamine dysfunction underlies the pathoetiology of psychosis in both bipolar disorder and schizophrenia.
Researchers conducted a prospective case-control study to examine predictors of early and late-onset psychosis in Parkinson disease.
These findings suggest that there are critical periods of development associated with a higher risk of persistent negative symptoms.
In this study, 672 patients with schizophrenia were evaluated with the EPICOG-SCH brief cognitive battery.
Seven signs and symptoms might alert someone to the possible presentation of schizophrenia.
Type 2 diabetes is greater with second-generation antipsychotics than with non-second-generation antipsychotic psychotropic medications for patients aged 6 to 25 years.
The FDA issued a refusal to file letter for a new drug application.
Switching therapy to Aristada resulted in statistically significant and clinically meaningful improvement in schizophrenia symptoms.
Adding telmisartan to treatment with olanzapine or clozapine may improve symptoms of schizophrenia.
Researchers from the University of Texas Southwestern Medical Center have discovered the cellular receptor that causes weight gain from antipsychotic drugs.
Long-term treatment of schizophrenia with cariprazine was found to be both safe and well-tolerated.
The FDA has approved Austedo.
Children and adolescent offspring of patients with schizophrenia demonstrate more attenuated psychotic symptoms.
Glucose tolerance and body mass index in patients with schizophrenia were improved by liraglutide.
Patients with schizophrenia in the MIN-101 trial demonstrated lower negative factor scores than a placebo group.
Impaired recollection could be a vulnerability marker for schizophrenia, whereas impaired social context memory could be a disease-related marker.
Schizophrenia treatment with long-acting injectable antipsychotic agents resulted in lower rehospitalization rates.
Clozapine-induced gastrointestinal hypomotility is a medical emergency that requires urgent attention.
A high percentage of patients were persistent and adherent to their PP3M treatment.
Clozapine might lower risk of self-harm for patients with treatment-resistant schizophrenia.
HIV, hepatitis B and hepatitis C are more common among patients with mental illnesses.
Interventions targeted at improving medication adherence might mitigate adverse effects of cannabis use on psychosis outcomes.
Long-acting injectables should be considered earlier in the treatment of schizophrenia.
Child maltreatment is significantly more prevalent in young individuals who present with UHR symptoms compared with controls.
Increases in autonomic function may predict the occurrence and severity of auditory hallucinations in patients with schizophrenia, suggesting a regulation of these experiences by the autonomic nervous system.
Diabetes mellitus (DM) appears to be more prevalent in the psychiatric setting than in the general population.
The risk for rehospitalization was 22% lower during treatment with long-acting injectable antipsychotic medications compared with treatment with equivalent oral formulations in the total cohort.
Schizophrenia patients may benefit from a a specific type of talk therapy, according to a new study from the University of Pennsylvania.
Concomitant SSRI/SNRI use was associated with an increased diabetes risk in AAP-treated young people.
There is currently no approved drug combination for treatment-resistant schizophrenia.
In patients with schizophrenia being treated with clozapine or olanzapine, liraglutide significantly improved glucose tolerance, body weight, and other cardiometabolic disturbances.
Electroconvulsive therapy can be a clinically effective treatment for patients with severe forms of schizophrenia.
Emotional stability assessed in late adolescence is inversely associated with serious mental illness.
Long-term valbenazine may be beneficial in managing tardive dyskinesia.
Body mass index in patients with schizophrenia is linked to C-reactive protein.
Schizophrenia outpatients were examined in this 52-week open-label extension trial.
Lurasidone is an atypical antipsychotic that has demonstrated efficacy in the treatment of schizophrenia in adolescents.
Dopamine-blocking antipsychotics are ineffective right from the onset of illness.
Mental disorders and psychotropic medication use are associated with an increased risk for fracture but are not fully captured by FRAX tool.
Schizophrenia was perceived as more distressful and with higher perceived social stigma than other disorders.
Scientists researched the association between multiple drug treatments for psychotic disorders and anticholinergic burden.
Ingrezza significantly and rapidly improved tardive dyskinesia symptoms compared to placebo, rmarking a tremendous breakthrough for patients suffering from TD.
Cannabis is the most widely misused illicit drug.
Schizophrenia was associated with 13 to 15 years of potential life lost.
The risk for offspring's development of psychosis is connected to maternal weight gain during pregnancy.
A trial at 3 mental health centers in The Netherlands revealed that patients with financial incentives have better compliance.
Participants in the risperidone group were generally more likely to achieve a significant clinical improvement in their mental state.
Cariprazine treatment led to greater improvement in the negative symptoms of schizophrenia than risperidone.
Adding high-dose B vitamins to traditional antipsychotic treatments reduces schizophrenia symptoms more than traditional treatments alone.
The FDA has approved a new treatment for adolescents between the ages of 13 and 17 years who are diagnosed with schizophrenia.
Researchers profiled which young people may do well after first-episode psychosis without medication.
These study results indicate that early intervention with low doses of metformin in patients with few metabolic abnormalities may be beneficial.
Targeting negative symptoms in patients with schizophrenia may be more effective in improving patients' QoL.
Pretreatment cardiometabolic status to be taken into consideration for treatment of first episode psychosis.
Inability to interpret facial expressions may exacerbate psychotic symptoms, either indirectly via social defeat or directly by creating confusing interpersonal experiences.
Cardiac safety is integral to child and adolescent antipsychotic therapy.
Patients with early schizophrenia may have already started down the road to diabetes, even prior to actual diagnosis.
Both immediate and gradual discontinuation of the current antipsychotic medication are viable treatment options.
Clinical practice guidelines are important resources for early intervention in a first episode of schizophrenia.
Young patients with first-episode psychosis may be able to achieve recovery.
This case offers evidence of the interaction between ciprofloxacin and clozapine.
Combined cognitive therapy and mindfulness can have lasting positive effects on behavior and mood.
Benefits of NMDA receptor agonists in patients with schizophrenia include improvements with memory and reading.
PUFA supplementation offers little additional aid to psychosis when good psychosocial care is already sought.
Hyperprolactinemia should be monitored during long-term risperidone treatment.
Sunovion have announced positive results from a study evaluating Latuda (lurasidone HCI) for the treatment of schizophrenia in adolescents aged 13 to 17 years old.
40-Hz ASSR spectral power and phase-locking deficits could be useful probes for assessing circuit dysfunctions in the disorder.
The findings might help to explain the increased prevalence of type 2 diabetes in patients with schizophrenia.
Studying cognition deficits during the clinical high risk period allows researchers to observe cognitive defects before chronicity and long-term medication use obscure the core deficits.
Medications used to treat addiction cut the risk of reoffending in half.
Indicators of schizophrenia, obsessive-compulsive disorder, and anxiety might be spotted in physical symptoms at age 18.
The Effect of Cognitive Remediation Training on Functional Connectivity and Social Cognition in Schizophrenia
Study provides further evidence for the effects of cognitive enhancement intervention on brain functional connectivity and cognitive performance in patients with schizophrenia.
Data indicate that 693 genes are differentially expressed between individuals diagnosed with schizophrenia and typical, healthy controls.
Researchers conducted an fMRI study of decision-making under conditions of risk and ambiguity in patients diagnosed with schizophrenia.
Researchers studied social cognition and social problem solving in patients with schizophrenia by employing a validated test designed to assess emotion recognition abilities.
Study provides further evidence for the effects of white matter fiber abnormalities and neuroinflammation on positive symptoms in patients with schizophrenia.
New findings provide an insight about the association between white matter microstructure and the severity of schizophrenia clinical symptoms.
Interaction of Proline and COMT Genotype Influences Negative Symptoms in Schizophrenia & Bipolar Disorder
The authors explored whether valproate (VPA) treatment effects vary by catechol-O-methyltransferase (COMT) genotype.
Researchers used voxel-based morphometry, which allows examination on a voxel-wise basis across the whole brain, to assess whether structural abnormalities in schizophrenia are static or progressive.
Poor psychosocial functioning among individuals diagnosed with schizophrenia is associated with deficits in social cognition.
TSPO expression is frequently used as a biomarker for brain inflammation during PET imaging.
Low physical activity was defined as less than 150 minutes of moderate-to-vigorous exercise per week.
Researchers used the auditory mismatch negativity (MMN) paradigm to evaluate its potential as a neurophysiological biomarker for psychosis.
Investigators examined the white matter tracts in patients diagnosed with the schizophrenia with predominantly negative symptoms.
Researchers explored the role of the dysregulated cannabinoid receptor system in patients diagnosed with schizophrenia.
The primary outcome in this study was reliability of patient-ratings on subjective well-being.
The primary outcome in this study was the change in total quality-of-life scores from baseline to week 24 after patients were randomly assigned to a treatment group.
Direct comparison of white matter tracts between individuals with schizophrenia or bipolar disorder has not been performed to date.
Psychosocial and Demographic Predictors of Depression Among Individuals With Bipolar Disorder and Schizophrenia
Bipolar disorder and schizophrenia are characterized by significant genetic overlap, as well as significant clinical presentation overlap.
Typical Brain Maturation Reveals Clues to Clinical Manifestation of Psychiatric Disorders in Adolescence
The authors examined measurements of cortical thickness and intracortical magnetization transfer (MT), a validated MRI marker for myelination, over time with regards to genomic patterning.
Previous studies comparing the hippocampal volume of at-risk mental state (ARMS) and first-episode psychosis (FEP) patients have produced mixed findings.
The researchers quantified the transcript levels of GAD67, parvalbumin, somastatin, and Lhx6 in the prefrontal cortex.
The researchers referred to their risk calculator as "well-performing."
Whereas the expression levels of CDK4 and MCM7 were significantly decreased only in the acute state, POLD4 was significantly decreased in the acute and remission states in the patients diagnosed with schizophrenia.
So far, the clinical presentation of psychosis in childhood and adolescence has only been examined in a small number of studies which are limited by small sample sizes.
Commonly used medications have been linked to an increased risk of hospitalization for dehydration and heat-related illness.
A diagnosis of schizophrenia and a length of stay of 90 days or more are the strongest predictors of polypharmacy.
At 12 months, researchers found a significant association between smoking reduction and suicidality.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Monetary Incentives Improve Cessation in Mentally Ill Smokers
- Obsessive Compulsive Disorder Associated With Decreased Educational Attainment
- Fluvoxamine Effective for Depression in Patients With Neurological Disorders
- When and How to Initiate Driving Cessation Conversation for Dementia Patients
- Memory Scores Have Limited Value as Early Alzheimer Disease Screening Tools
- Nutritional Psychiatry: Emerging Evidence and Expert Interview
- FDA Approval: Once-Monthly Buprenorphine Injection for Opioid Use Disorder
- Posttreatment Brain Effects of Psilocybin in Patients With Treatment-Resistant Depression
- Bipolar Disorder, Borderline Personality Disorder May Represent the Same Disorder
- Borderline Personality Disorder: Not Just an Adult Condition
- Depression Screening Tools Accurate in Post-Acute Coronary Syndrome
- Antidepressant Effectiveness for Depression in Schizophrenia
- Higher Rates of Psychotic Incidence in Younger Men, Racial Minorities
- Healthcare Inequality in America: Senator Bernie Sanders's Advisors on Causes and Solutions
- Code of Ethics and New Regulations for Human Research